Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

EMERGENT BIOSOLUTIONS INC.

(EBS)
  Report
Delayed Nyse  -  04:00:02 2023-01-27 pm EST
13.47 USD   +2.67%
01/26FDA identifies recall of Emergent's decontamination kits as most serious
RE
01/10U.S. FDA panel to review Emergent's OTC opioid overdose drug
RE
01/09Emergent BioSolutions Says Preliminary 2022 Revenue Seen Down About 38%; To Reduce Workforce by 5%
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 2 7854 7492 339672672-
Enterprise Value (EV)1 3 4285 0022 6031 5031 3581 135
P/E ratio 51,9x15,8x10,2x-3,46x118x21,0x
Yield ------
Capitalization / Revenue 2,52x3,05x1,30x0,61x0,57x0,57x
EV / Revenue 3,10x3,22x1,45x1,37x1,16x0,97x
EV / EBITDA 12,3x7,94x5,03x35,8x7,22x-
Enterprise Value (EV) / FCF 33,9x12,7x27,1x-4,64x6,48x10,7x
FCF Yield 2,95%7,90%3,69%-21,6%15,4%9,34%
Price to Book 2,55x3,29x1,38x0,48x0,47x0,45x
Nbr of stocks (in thousands) 51 62452 99953 79949 88849 888-
Reference price (USD) 54,089,643,513,513,513,5
Announcement Date 02/20/202002/18/202102/24/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 1 1061 5551 7931 1001 1691 171
EBITDA1 28063051842,0188-
Operating profit (EBIT)1 114434353-16441,475,5
Operating Margin 10,3%27,9%19,7%-14,9%3,54%6,45%
Pre-Tax Profit (EBT)1 77,4407314-2165,9239,7
Net income1 54,5305231-191-0,1232,3
Net margin 4,93%19,6%12,9%-17,3%-0,01%2,76%
EPS2 1,045,674,27-3,890,110,64
Free Cash Flow1 10139596,1-324210106
FCF margin 9,14%25,4%5,36%-29,5%17,9%9,05%
FCF Conversion 36,1%62,7%18,6%-771%111%-
Dividend per Share ------
Announcement Date 02/20/202002/18/202102/24/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2
Net sales1 308243240309236339
EBITDA1 36,0-28,8-15,258,5--
Operating profit (EBIT)1 6,40-72,0-42,0-56,5-6,0025,5
Operating Margin 2,08%-29,7%-17,5%-18,3%-2,54%7,53%
Pre-Tax Profit (EBT)1 -3,80-82,8-63,9-66,0-13,617,9
Net income1 -3,70-56,4-75,7-54,4-13,518,0
Net margin -1,20%-23,2%-31,5%-17,6%-5,72%5,31%
EPS2 -0,07-1,13-1,52-1,17-0,440,43
Dividend per Share ------
Announcement Date 04/28/202208/01/202211/08/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 643254265831686463
Net Cash position1 ------
Leverage (Debt / EBITDA) 2,30x0,40x0,51x19,8x3,65x-
Free Cash Flow1 10139596,1-324210106
ROE (Net Profit / Equities) 14,5%33,4%21,2%-4,91%3,41%5,52%
Shareholders' equity1 3769121 0873 883-3,51585
ROA (Net Profit / Asset) 6,68%16,3%11,1%-2,55%1,72%2,93%
Assets1 8161 8752 0717 476-6,971 101
Book Value Per Share2 21,127,331,628,128,830,1
Cash Flow per Share ------
Capex1 86,914122581,070,545,0
Capex / Sales 7,86%9,07%12,6%7,36%6,03%3,84%
Announcement Date 02/20/202002/18/202102/24/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Key data
Capitalization (USD) 671 994 296
Net sales (USD) 1 792 700 000
Number of employees 2 416
Sales / Employee (USD) 742 012
Free-Float 80,8%
Free-Float capitalization (USD) 542 707 997
Avg. Exchange 20 sessions (USD) 11 665 533
Average Daily Capital Traded 1,74%
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA